Endovaskulární léčba ischemických cévních mozkových příhod

Antonín Krajina, Dagmar Krajíčková

Interv Akut Kardiol. 2015;14(1):7-8  

Pentraxin 3 and interleukin 18 in the course of acute myocardial infarction

Lucie Horáková, Radek Pudil, Ctirad Andrýs, Jan Vojáček

Interv Akut Kardiol. 2015;14(1):10-13  

Aim: The rupture of atherosclerotic plaques is responsible for acute myocardial infarction with all its consequences. We have studied the changes in concentrations of new two markers (PTX3, IL18) in the patients with myocardial infarction and their relation to myocardial dysfunction. Material and methods: This study includes 29 patients with acute myocardial infarction and we have investigated these markers: pentraxin 3 (PTX3), interleukin 18 (IL-18), high sensitive troponin (hsTnT) and glycogenphosphorylase BB (GPBB). Samples were taken on the day of admission, after 24 hours and on the fourth or fifth day of hospitalization. Monitored parameters...

Troponins and minimal myocardial damage after pacemaker implantation - pilot study

Tomáš Hnátek, Miloš Táborský, Martin Malý, Libor Kameník, Simona Littnerová, Pavel Sedloň, Jana Luxová, Marta Fišerová, Šárka Hamouzová, Miroslav Zavoral

Interv Akut Kardiol. 2015;14(1):14-17  

Introduction: Cardiac troponins are highly specific markers of myocardial damage. The aim of our investigation was to determine the correlation between pacemaker implantation and elevation of cardiospecific markers. Aim: To compare the elevation of troponin I in group of patients with the implantation of pacemaker (single or dual chamber) with active lead and unselected population of cardiologic patients. Method: A defined group of 230 patients were indicated for the pacemaker implantation. The values of cardiospecific markers (troponin I, CKMB and myoglobin) were measured before the implantation and repeated 6 and 18 hours later. Monitored...

Epicardial fat - characteristics and significance

Jana Mlynárová, Andrea Gažová, Ondrej Sprušanský, Peter Musil, Eva Goncalvesová, Ján Kyselovič

Interv Akut Kardiol. 2015;14(1):18-21  

Epicardial fat is concentrated in the atrioventricular and interventricular grooves and along the major branches of the coronary arteries, and, to a lesser extent, around the atria, over the free wall of the right ventricle and over the apex of the left ventricle. Epicardial fat covers 80 % of the heart’s surface and constitutes 20 % of total heart weight. Epicardial fat is a metabolically active organ that generates various bioactive molecules, which might significantly affect cardiac function. Further studies of this neglected tissue and its relationship with cardiac function, as well as of its use as a marker of metabolic and cardiovascular...

Cardiomarkers in diagnostics of the heart failure

Radek Pudil

Interv Akut Kardiol. 2015;14(1):22-25  

The article presents an overview of the current possibilities of the clinical use of cardiac markers in the diagnostics of heart failure. It focuses primarily on natriuretic peptides, and it provides a basic knowledge of their origin and effect on the cardiovascular system. It brings information about a preanalytical issue. The information about new potentially interesting markers (mid-regional pro-ANP and mid-regional pro-adrenomedullin) is included.

Novel oral anticoagulants in treatment of acute coronary syndrome

Karel Kopřiva, Petr Neužil

Interv Akut Kardiol. 2015;14(1):26-30  

Dual antiplatelet therapy is a standard component of secondary prevention in patients with acute coronary syndrome (ACS). In spite of this, there remains an increased risk of myocardial infarction (MI) and cardiovascular death in these patients. Given the pathophysiological mechanism of ACS, long-term anticoagulant therapy appears to be one of the options of how to further reduce this risk. Nowadays, novel oral anticoagulants (NOACs) are routinely used to treat venous thrombosis as well as to prevent stroke and systemic embolism in atrial fibrillation. Several agents of this group have been tested in clinical trials in the indication of secondary...

Mitral valve replacement in the complete form of atrio-ventricular septal defect in infancy

Žaneta Bandžuchová, Viktor Tomek, Tomáš Tláskal, Jan Janoušek

Interv Akut Kardiol. 2015;14(1):32-34  

A five day old female newborn was diagnosed to have a complete form of atrio-ventricular septal defect, mitral insufficiency, stenosis of the left ventricular outflow tract and pulmonary hypertension. At the age of two months, the patient underwent surgical repair including supra-annular mechanical mitral valve replacement for significant residual mitral regurgitation. In later life the valve prosthesis had to be replaced twice for stenosis. The case report documents complex problems associated with mitral valve replacement in infancy.

Closure of persistent arterial duct in patient with hypoplastic femoral arteries

Marek Kardoš, Peter Tittel

Interv Akut Kardiol. 2015;14(1):35-36  

Persistent arterial duct (PDA) is one of the most common congenital heart diseases. Catheter-based closure of PDA represents an excelent therapeutic method. We present a case of catheter-based closure of PDA in patient with hypoplastic femoral arteries confirmed sonographically. Only venous access was used during catheterization which complicated angiographic visualization of PDA and then choice of right type and size of Amplatzer occluder.

Komentář k článku Urbánek P. Dostanou všichni pacienti s akutním infarktem myokardu v ČR srovnatelnou šanci na co nejlepší výsledek léčby? (Interv Akut Kardiol 2015; 14(1): 38-43)

Michael Želízko

Interv Akut Kardiol. 2015;14(1):44-46  

Will all patients with acute myocardial infarction in the Czech Republic

Pavel Urbánek

Interv Akut Kardiol. 2015;14(1):38-43  

get the same chance for best result of treatment? From the patient’s perspective, the delay between symptom onset and provision of reperfusion therapy is possibly the most important, since it reflects total ischaemic time. It should be reduced as much as possible! So is written in ESC Gudelines and also in Summary of recommended procedures from ESC for diagnosis and treatment of myocardial infarction with STE from 2012. Opening of closed coronary artery is possible in two ways: by percutaneous intervention in catheterization center or by administrating thrombolytics, preferably during the first contact with the patient. The first procedure...